Pertuzumab and the Curious Case of Accelerated Registration
Drs Kathy Miller, Clifford Hudis, and George Sledge discuss the pros and cons of testing novel breast cancer treatments in the neoadjuvant setting, with special reference to pertuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Sorting Therapy Options in Locoregional Breast Cancer
Drs Richard Zellar and Kathy Miller, at SABCS 2014, discuss locoregional breast cancer therapies, including partial breast irradiation, surgery vs radiation of sentinel nodes, and DCIS scoring. (Source: Medscape Oncology)
Source: Medscape Oncology - February 5, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Pembrolizumab Boasts Benefit, Tolerability in Gastric Cancer
Dr Brandon Smaglo reports on 2 studies from 2015 GCIS, one showing benefit from pembrolizumab in gastric cancer, another suggesting that less palliative therapy may be warranted in esophageal cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - February 3, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Anti-PD-L1 Boasts Benefit, Tolerability in Gastric Cancer
Dr Brandon Smaglo reports on 2 studies from 2015 GCIS, one showing benefit from pembrolizumab in gastric cancer, another suggesting that less palliative therapy may be warranted in esophageal cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - February 3, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
EGFR Mutant Lung Cancer: Lessons From ASPIRATION and IMPRESS
Dr Mark Kris discusses the switch from first- to second-line therapy for EGFR mutant lung cancers in light of two studies presented at the most recent ESMO meeting. (Source: Medscape Oncology)
Source: Medscape Oncology - January 29, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
The Case for Neoadjuvant Therapy in Lung Cancer
Dr Mark Kris discusses the benefits of neoadjuvant therapy for patients with locally advanced lung cancers, from treating micrometastases to assessing response to therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - January 16, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Four Years After NLST, Lung Screening Uptake 'Way Too Slow'
Dr Mark Kris reviews recent developments in lung cancer screening and calls on the oncology community to recommend screening to all eligible candidates. (Source: Medscape Oncology)
Source: Medscape Oncology - January 14, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Cancer Death the Best? David Kerr Begs to Differ
Dr David Kerr responds to Richard Smith's provocative blog post, 'Dying of Cancer Is the Best Death,' and calls his fellow Brit 'daft' for saying we should stop spending billions to overcome cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - January 12, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Getting a (Glass) Bead on CRC Metastases
Dr David Kerr reports on mounting evidence of the significant antitumor activity of yttrium-90 in hepatic metastatic CRC when Y90 microspheres are delivered via the hepatic artery. (Source: Medscape Oncology)
Source: Medscape Oncology - January 12, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Cervical Cancer Is Preventable
If opportunities to screen for cervical cancer or vaccinate for HPV were not missed, cervical cancer rates would plummet. (Source: Medscape Oncology)
Source: Medscape Oncology - January 5, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Active Surveillance OK With HGPIN or ASAP on Biopsy
Concomitant high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) should not preclude the patient from active surveillance, reports Dr Gerald Chodak. (Source: Medscape Oncology)
Source: Medscape Oncology - December 26, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Can Molecular Profiling Lower Cancer Costs?
Dr John Marshall asks tough questions of experts at the 2014 Ruesch Symposium about whether information gained from molecular testing can tailor therapy and lower costs. (Source: Medscape Oncology)
Source: Medscape Oncology - December 24, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Countdown to GI Immunotherapy
How close are we to practice-changing scores that determine a patient's risk and type of treatment needed? Experts at the 2014 Ruesch Symposium estimate that real-time immunotherapy is almost here. (Source: Medscape Oncology)
Source: Medscape Oncology - December 24, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Weight Loss WINS in Breast Cancer
Women overweight when diagnosed with breast cancer have poorer outcomes. Drs Kathy Miller and Jennifer Ligibel discuss how to motivate patients to alter their lifestyles to lower their risk. (Source: Medscape Oncology)
Source: Medscape Oncology - December 24, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
SABCS Wrap-up: Will TNT Quietly Change Practice?
Drs Kathy Miller and George Sledge review the surprises and intrigues of SABCS, from its start in 1977 to the best scientific and practice-changing studies presented in 2014. (Source: Medscape Oncology)
Source: Medscape Oncology - December 22, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
